Haematological care of the Jehovah's witness patient

British Journal of Haematology

Volumn 119, Issue 1, 2002, Pages 25-37

  Marsh, Judith C W ^a   Bevan, David H ^a  

^a ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Consent; Jehovah's witnesses; Leukaemia; Transfusion

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXTRAN; ENOCITABINE; ETOPOSIDE; FLUDARABINE; GELATIN SUCCINATE; GRANULOCYTE COLONY STIMULATING FACTOR; HETASTARCH; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; POLYGELINE; PREDNISONE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT ERYTHROPOIETIN; VINCRISTINE; VINDESINE;

ACUTE LEUKEMIA; AGE; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; DRUG CHOICE; EMERGENCY TREATMENT; GOOD CLINICAL PRACTICE; HEALTH CARE POLICY; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMODILUTION; HEMOPHILIA A; HUMAN; INFORMED CONSENT; MEDICAL DECISION MAKING; MEDICAL ETHICS; PRIORITY JOURNAL; RELIGIOUS GROUP; SICKLE CELL ANEMIA; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION; CHILD; HEMATOLOGIC DISEASES; HUMANS; INFORMED CONSENT; JEHOVAH'S WITNESSES; PRACTICE GUIDELINES;

EID: 0036398459     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2002.03639.x     Document Type: Article

References (69)

1. Archimbaud, E., Ottmann, O., Liu Yin, J.A., Lechner, K., Dombret, H., Sanz, M.A., Herrmann, F., Gruss, H., Fenaux, P., Ganser, A., Heil, G., Kanz, L., Brugger, W., Sims, T., Olsen, K. & Hoelzer, D. (1996) A randomised double-blind, placebo-controlled study using PEG-rHuMGDF as an adjunct to chemotherapy for adults with de novo acute myeloid leukaemia: early results. Blood, 88, 447a.
2. Association of Anaesthetists of Great Britain and Ireland (1999) Management of Anaesthesia for Jehovahs' Witnesses.
3. Ballen, K.K., Ford, P.A., Waitkus, H., Emmons, R.V., Levy, W., Doyle, P., Stewart, F.M., Quesenberry, P.J. & Becker, P.S. (2000) Successful autologous bone marrow transplant without the use of blood product support. Bone Marrow Transplantation, 26, 227-229.
4. Basser, R.L., Rasko, J., Clarke, K., Cebon, J., Green, M.D., Grigg, A., Zalcberg, J., Cohen, B., O'Bryne, J., Menchaca, D.M., Fox, R.M. & Begley, C.G. (1997) Randomised, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood, 89, 3118-3128.
5. Bell, K., Stott, K., Sinclair, C.J. & Gillon, J. (1992) A controlled trial of intraoperative autologous transfusion in cardiothoracic surgery measuring effect on transfusion requirements and clinical outcome. Transfusion Medicine, 2, 295-300.
6. Blutters-Sawatzki, R. & Bertram, U. (1992) Introduction of erythropoietin in the treatment of acute lymphoblastic leukemia (ALL) in a patient of Jehovah's Witnesses Persuasion: a case report. Medical and Pediatric Oncology, 2, 23-25.
7. Boggs, D.R. (1985) Jehovah's Witnesses with leukemia. Hospital Practice, 20, 92-98.
8. British Committee for Standards in Haematology, Blood Transfusion Task Force (2001) Guidelines for the clinical use of red cell transfusions. British Journal of Haematology, 113, 24-31.
9. Broccia, G. (1994) Long term continuous complete remission of acute myeloid leukemia in a Jehovah's Witness treated without blood support. Haematologica, 79, 180-181.
10. Camitta, B.M., Thomas, E.D., Nathan, D.G., Santos, G., Gordon-Smith, E.C., Gale, R.P., Rappeport, J.M. & Storb, R. (1976) Severe aplastic anemia: a prospective study on the effect of early marrow transplantation on acute mortality. Blood, 48, 63-70.
11. Carson, J.L., Duff, A., Berlin, J.A., Lawrence, V.A., Poses, R.M., Huber, E.C., O'Hara, D.A., Noveck, H. & Strom, B.L. (1998) Perioperative blood transfusion and post operative mortality. Journal of the American Association of Medicine, 279, 199-205.
12. Cazzola, M., Mercuriali, F. & Brugnan, C. (1997) Use of recombinant human erythropoietin outside the setting of uremia. Blood, 89, 4248-4267.
13. Clagett, G.P., Valentine, R.J. & Jackson, M.R. (1999) A randomised trial of intraoperative transfusion during aortic surgery. Journal of Vascular Surgery, 29, 22-30.
14. Clay, M.A. (1999) Ethical and legal implications of bloodless medicine and surgery. Journal of Intensive Care Medicine, 14, 34-40.
15. Corash, L. (2000) New technologies for the inactivation of infectious pathogens in cellular blood components and the development of platelet substitutes. Bailliere's Clinical Haematology, 13, 549-563.
16. Couban, S. & Wilson, W.E.C. (1995) Use of 2-chlorode-oxyadenosine, granulocyte-colony stimulating factor, and erythropoietin in a Jehovah's Witness with hairy cell leukaemia. American Journal of Hematology, 49, 255-256.
17. Cullis, J.O. & Smith, A.G. (1990) Jehovah's Witnesses with leukaemia. Lancet, 336, 1075-1076.
18. Cullis, J.O., Duncombe, A.S., Dudley, J.M., Lumley, H.S., Apperley, J.F. & Smith, A.G. (1998) Acute leukemia in Jehovah's Witnesses. British Journal of Haematology, 100, 664-668.
19. D'Oiron, R., Menart, C., Trzeciak, M.C., Nurden, P., Fressinaud, E., Dreyfus, M., Laurian, Y. & Negrier, C. (2000) Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thrombasthenia undergoing invasive procedures. Thrombosis and Haemaostasis, 83, 644-647.
20. Dainer, P.M., Knupp, C.L. & Sartiano, G.P. (1992) Low dose cytosine arabinoside as an alternative treatment for acute leukemia in Jehovah's Witnesses. American Journal of Hematology, 40, 156-157.
21. Desmond, M.J., Thomas, M.J., Gillon, J. & Fox, M.A. (1996) Consensus conference on autologous transfusion. Perioperative red cell salvage. Transfusion, 36, 644-651.
22. Desmond, M., Gillon, J. & Thomas, M.J.G. (1999) Perioperative red cell salvage: a case for implementing the consensus statement. Transfusion Medicine, 9, 265-268.
23. Elder, L. (2000) Why some Jehovah's Witnesses accept blood and conscientiously reject official Watchtower Society blood policy. Journal of Medical Ethics, 26, 375-380.
24. Estrin, J.T., Ford, P.A., Henry, D.H., Stradden, A.P. & Mason, B.A. (1997) Erythropoietin permits high-dose chemotherapy with peripheral blood stem-cell transplant for a Jehovah's Witness. American Journal of Hematology, 55, 51-52.
25. Fanucchi, M., Glaspy, J., Crawford, J., Garst, J., Figlin, R., Sheridan, W., Menchaca, D., Tomita, D., Ozer, H. & Harker, L. (1997) Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. New England Journal of Medicine, 336, 404-409.
26. Frickhofen, N. & Rosenfeld, S.J. (2000) Immunosuppressive therapy of aplastic anaemia with antithymocyte globulin and cyclosporine. Seminars in Hematology, 37, 56-68.
27. Gillon, R. (2000) Refusal of potentially life-saving blood transfusions by Jehovah's Witnesses: should doctors explain that not all JWs think it's religiously required? Journal of Medical Ethics, 26, 299-301.
28. Goldberg, S.L., Chan, C.S.P., Dawkins, F.W., Mehlman, M.D. & Schechter, G.P. (1990) Should Jehovah's Witnesses be denied intensive chemotherapy for acute leukemia? New England Journal of Medicine, 322, 777.
29. Goodnough, L.T., Monk, T.G. & Brecher, M.E. (1998) Acute normovolaemic hemodilution should replace the preoperative donation of autologous blood as a method of autologous-blood procurement. Transfusion, 38, 473-476.
30. Goodnough, L.T., Brecher, M.E., Kanter, M.H. & AuBuchon, J.P. (1999a) Transfusion medicine, first of two parts: blood transfusion. New England Journal of Medicine, 340, 438-447.
31. Goodnough, L.T., Brecher, M.E., Kante, M.H. & AuBuchon, J.P. (1999b) Transfusion medicine, second of two parts: blood conservation. New England Journal of Medicine, 340, 525-533.
32. Hargis. J.B., Waddell, D.J., Diehl, L. & Redmond, J. (1990) Induction chemotherapy in Jehovah's Witnesses with leukaemia. Lancet, 336, 563-564.
33. Hedner, U. (1999) Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa. Thrombosis and Haemostasis, 82, 531-534.
34. Heimpel, H. (1993) Therapy of aplastic anaemia: is a consensus possible?. In: Aplastic Anaemia: Current Perspectives on the Pathogenesis and Treatment (ed. by H. Schrezenmeier & N. Frickhofen), pp. 154-159. Blackwell-MZV, Holland.
35. Herbert, P.C., Wells, G., Morris, A., Blajchman, M.A., Marshall, J., Martin, C., Pagliavello, G., Tweeddale, M., Schweitzer, I., Yetisir, E. & the Transfusion Requirements in Critical Care Iinvestigators for the Canadian Critical Care Trials Group (1999) A multi-center, randomised, controlled clinical trial of transfusion requirements in critical care. New England Journal of Medicine, 340, 409-417.
36. Hoffman, M., Monroe, III, D.M. & Roberts, H.R. (1998) Activated factor VIIa activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagulation and Fibrinolysis, 9, S61-S65.
37. Kaito, K., Kobayashi, M., Sakamoto, M., Shimada, T., Masuoka, H., Nishiwaki, K., Saeki, A., Sekita, T., Otsubo, H. & Hosoya, T. (1998) Combination chemotherapy with G-CSF, M-CSF and Epo: successful treatment for acute myelogenous leukemia without blood transfusion at lower medical costs. Acta Haematologica, 100, 57-60.
38. Kaushansky, K. (2000) Use of thrombopoietic growth factors in acute leukaemia. Leukaemia, 14, 505-508.
39. Kerridge, I., Lowe, M., Seldon, M., Enno, A. & Deveridge, S. (1997) Clinical and ethical issues in the treatment of a Jehovah's Witness with acute myeloblastic leukemia. Archives of Internal Medicine, 157, 1753-1757.
40. Klein, H.G. (2000) The prospects for red-cell substitutes. New England Journal of Medicine, 342, 1666-1668.
41. Lin, C.-P., Huang, M.-J., Liu, H.-J. & Tsai, C.-H. (1996) Successful treatment of acute promyelocytic leukemia in a pregnant Jehovah's Witness with all-trans retinoic acid, rhG-CSF, and erythropoietin. American Journal of Hematology, 51, 251-252.
42. Malyon, D. (1998) Transfusion-free treatment of Jehovah's Witnesses: respecting the autonomous patient's rights. Journal of Medical Ethics, 24, 302-307.
43. Marsh, J.C.W. (2000) Hematopoietic growth factors in the pathogenesis and for the treatment of aplastic anemia. Seminars in Hematology, 37, 81-90.
44. Mason, J.K. & McCall Smith, R.A. (1994) Law and Medical Ethics, 4th edn, pp. 229-231. Butterworths, London.
45. Mazza, P., Palazzo, G., Amurri, B., Cervellera, M., Rizzo, C. & Maggi, A. (2000) Acute leukemia in Jehovah's Witnesses: a challenge for hematologists. Haematologica, 85, 1221-1222.
46. Menedez, A., Svarch, E., Martinez, G. & Hernandez, P. (1998) Successful treatment of acute promyelocytic leukemia using all-trans retinoic acid and erythropoietin in a Jehovah's Witness boy. Annals of Hematology, 76, 43-44.
47. Muramoto, O. (2000) Medical confidentiality and the protection of Jehovah's Witnesses' autonomous refusal of blood. Journal of Medical Ethics, 26, 381-386.
48. Muramoto, O. (2001) Bioethical aspects of the recent changes in the policy of refusal of blood by Jehovah's Witnesses. British Medical Journal, 322, 37-39.
49. NHS Executive (1998) Health Service Circular. Better Blood Transfusion HSC224. NHS, London.
50. Nousiainen, T., Jantunen, E. & Lahtinen, R. (1993) Jehovahs' Witnesses with acute leukemia. American Journal of Hematology, 43, 158-159.
51. Pegelow, C.H., Adams, R.J., McKie, V., Abboud, M., Berman, B., Miller, S.T., Olivieri, N., Vichinsky, E., Wang, W. & Brambilla, D. (1995) Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. Journal of Pediatrics, 126, 896-899.
52. Re, S. (1992) (A Minor) (Medical Treatment) 4 All ER 671.
53. Re, T. (1992) (Adult) (Refusal of Medical Treatment) 4 All ER 649, 9 BMLR 46, CA.
54. Ridley, D. (1999) Jehovah's Witnesses refusal of blood: obedience to scripture and religious conscience. Journal of Medical Ethics, 25, 469-472.
55. Rohling, R.G., Zimmerman, A.P. & Breymann, C. (2000) Intravenous versus oral iron supplementation for preoperative stimulation of hemoglobin synthesis using recombinant human erythropoietin. Journal of Hematotherapy and Stem Cell Research, 9, 497-500.
56. Royal College of Physicians of Edinburgh (1996) Consensus conference on autologous transfusion: final consensus statement. Transfusion, 36, 667.
57. Royal College of Physicians of Edinburgh (1999) Autologous transfusion, 3 years on: What is new? What has happened? Transfusion, 39, 910-911.
58. Royal College of Surgeons of England (1996) Code of Practice for the Surgical Management of Jehovah's Witnesses.
59. Samuelsson, G. (2001) Extracorporeal immunoadsorption with protein A: technical aspects and clinical results. Journal of Clinical Apheresis, 16, 49-52.
60. Sievers, E.L., Larson, R.A., Stadtmauer, E.A., Estey, E., Lowenberg, B., Dombret, H., Karanes, C., Theobald, M., Bennett, J.M., Sherman, M.L., Berger, M.S., Eten, C.B., Loken, M.R., van Dongen, J.J., Bernstein, I.D. & Appelbaum, F.R. (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD-33-positive acute myeloid leukaemia in first relapse. Journal of Clinical Oncology, 19, 3244-3254.
61. Smith, S. (2001) The role of the court in ethical decision making. Clinical Medicine (JRCPL), 1, 371-373.
62. Takeuchi, S., Utsunomiya, A., Makino, T., Shimotakahara, S., Takatsuka, Y., Kawabata, H. & Nakashima, A. (1999) Successful treatment for acute lymphoblastic leukemia without blood transfusion in a Jehovah's Witness. American Journal of Hematology, 60, 167-172.
63. Thomas, M.J.G. (1999) Infected and malignant fields are an absolute contraindication to intraoperative cell salvage: fact or fiction? Transfusion Medicine, 9, 269-278.
64. Viele, M.K. & Weiskopf, R.B. (1993) What can we learn about the need for transfusion from patients who refuse blood? The experience with Jehovah's Witnesses. Transfusion, 34, 396-401.
65. Watchtower Bible and Tract Society (1981) Disfellowship - how to view it. Watchtower, September 15, 20-26.
66. Watchtower Bible and Tract Society (2000) Questions from readers. Watchtower, June 15, 29-31.
67. Williamson, L.M., Lowe, S., Love, E.M., Cohen, H., Soldan, K., McClelland, D.B.L., Skacel, P. & Barbera, J.A.J. (1999) Serious hazards of transfusion (SHOT) initiative: analysis of the first two annual reports. British Medical Journal, 319, 16-19.
68. Williamson, K.R. & Taswell, H.F. (1991) Intraoperative blood salvage: a review. Transfusion, 31, 662-675.
69. Yate, R.M., Milling, M.A.P. & McFadzean, W. (2000) Treatment without consent: a medicolegal precedent. Lancet, 356, 69.